Sivik Global Healthcare LLC Bio N Tech Se Transaction History

Sivik Global Healthcare LLC

  • $190 Million
  • Q4 2024

A detailed history of Sivik Global Healthcare LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Sivik Global Healthcare LLC holds 15,000 shares of BNTX stock, worth $1.86 Million. This represents 0.9% of its overall portfolio holdings.

Number of Shares
15,000
Holding current value
$1.86 Million
% of portfolio
0.9%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 23, 2025
BUY
$99.72 - $122.68 $1.5 Million - $1.84 Million
15,000 New
15,000 $1.71 Million
Q1 2024

Apr 30, 2024
BUY
$88.96 - $112.35 $2.22 Million - $2.81 Million
25,000 New
25,000 $2.31 Million
Q4 2022

Feb 08, 2023
BUY
$118.43 - $186.05 $1.54 Million - $2.42 Million
13,000 New
13,000 $1.95 Million
Q2 2022

Aug 10, 2022
SELL
$123.25 - $186.24 $1.23 Million - $1.86 Million
-10,000 Closed
0 $0
Q1 2022

May 09, 2022
BUY
$126.25 - $231.85 $1.26 Million - $2.32 Million
10,000 New
10,000 $1.71 Million
Q2 2021

Aug 10, 2021
SELL
$113.32 - $241.49 $2.27 Million - $4.83 Million
-20,000 Closed
0 $0
Q1 2021

May 12, 2021
BUY
$85.73 - $119.5 $1.71 Million - $2.39 Million
20,000 New
20,000 $2.18 Million
Q3 2020

Nov 13, 2020
SELL
$57.81 - $104.17 $2.31 Million - $4.17 Million
-40,000 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$38.58 - $66.74 $1.54 Million - $2.67 Million
40,000 New
40,000 $2.67 Million

Others Institutions Holding BNTX

# of Institutions
360
Shares Held
38.3M
Call Options Held
2.45M
Put Options Held
2.29M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $30B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Sivik Global Healthcare LLC Portfolio

Follow Sivik Global Healthcare LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sivik Global Healthcare LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sivik Global Healthcare LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email